UCB has entered the red-hot T-cell engager (TCE) space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate. At the center of the deal is ATG-201, a CD19/CD3 ...
Antengene Corporation Limited (Antengene), a leading innovative, commercial-stage global biotech company, and UCB, a global ...
Climb Bio (NASDAQ:CLYM) outlined its strategy and upcoming clinical milestones during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, with Chief Medical Officer Edgar ...
UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody
UCB obtains worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseasesDeal ...
Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...
-Data demonstrate characteristics essential for treatment of autoimmune diseases, including robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue -Results highlight the ...
Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that its abstract detailing clinical results ongoing Phase 1/2 trial ...
Please provide your email address to receive an email when new articles are posted on . Most patients with B-cell lymphomas who relapsed after CAR T-cell therapy responded to the novel, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results